De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant gliomaDiana D. Shi, William G. Kaelin, Vinesh T. Puliyappadamba et al.|Cancer Cell|2022Cited by 132
Autochthonous tumors driven by <i>Rb1</i> loss have an ongoing requirement for the RBP2 histone demethylaseSamuel K. McBrayer, William G. Kaelin, Benjamin A. Olenchock et al.|Proceedings of the National Academy of Sciences|2018Cited by 16
De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant GliomaDiana D. Shi, Samuel K. McBrayer, Milan R. Savani et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 11
Identification of De Novo Pyrimidine Synthesis as a Targetable Vulnerability in a Novel IDH1 Mutant Engineered Astrocytoma ModelDerek Shi, Samuel K. McBrayer, A.C. Wang et al.|International Journal of Radiation Oncology*Biology*Physics|2021Cited by 2
TMOD-14. CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1-R132H ONCOGENEDiana D. Shi, Samuel K. McBrayer, Adam Wang et al.|Neuro-Oncology|2020Cited by 1